Hrk BH3 Domain Antibody Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O00198 |
---|---|
Other Accession | NP_003797 |
Clone Names | 2011201 |
Gene ID | 8739 |
---|---|
Other Names | Activator of apoptosis harakiri, BH3-interacting domain-containing protein 3, Neuronal death protein DP5, HRK, BID3 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP1311a was selected from the region of human Hrk BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | HRK |
---|---|
Synonyms | BID3 |
Function | Promotes apoptosis. |
Cellular Location | Membrane; Single-pass membrane protein. Mitochondrion |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Activator of apoptosis Hrk regulates apoptosis through interaction with death-repressor proteins Bcl-2 and Bcl-X(L). The HRK protein lacks significant homology to other BCL2 family members except for an 8-amino acid region that was similar to the BCL2 homology domain-3 (BH3) motif of BIK. HRK interacts with BCL2 and BCLXL via the BH3 domain, but not with the death-promoting BCL2-related proteins BAX, BAK, or BCLXS. HRK localizes to membranes of intracellular organelles in a pattern similar to that previously reported for BCL2 and BCLXL.
References
Wakabayashi, T., et al., Neurosci. Lett. 318(2):77-80 (2002).Inohara, N., et al., EMBO J. 16(7):1686-1694 (1997).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.